# CHRONIC LEUKEMIA


### BY:

DR. FATMA AL-QAHTANI

ASSOCIATE PROFESSOR
CONSULTANT HAEMATOPATHOLOGIST
DEPARTMENT OF PATHOLOGY


### **Chronic Leukaemias**

- Heterogeneous group of hematopoietic neoplasms
- Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation
- Composed of relatively mature cells
- Indolent. (If untreated, the course is in months or years)
- Occurs mainly in adults



# **Main Types of Leukemia**

	Acute	Chronic
Lymphoid	ALL	LPN(CLL)
Myeloid	AML	MPN/MDS (CML)
Mixed	Acute Biphenotypic	
Non	Acute Undifferentiated	



**Table 1.** Classification of Myeloid Neoplasms According to the 2008 World Health Organization Classification Scheme

### 1. Myeloproliferative neoplasms (MPN)

- 1.1. Chronic myelogenous leukemia, BCR-ABL1-positive (CML)
- 1.2. Polycythemia vera (PV)
- 1.3. Essential thrombocythemia (ET)
- 1.4. Primary myelofibrosis (PMF)
- 1.5. Chronic neutrophilic leukemia (CNL)
- Chronic eosinophilic leukemia, not otherwise specified (CEL-NOS)
- 1.7. Mast cell disease (MCD)
- 1.8. MPN, unclassifiable
- Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1

#### 3. MDS/MPN

- 3.1. Chronic myelomonocytic leukemia (CMML)
- 3.2. Juvenile myelomonocytic leukemia (JMML)
- Atypical chronic myeloid leukemia, BCR-ABL-negative (aCML)
- 3.4. MDS/MPN, unclassifiable
- 4. Myelodysplastic syndromes (MDS)
- 5. Acute myeloid leukemia (AML)

## **Myeloproliferative Neoplasms**


- Malignant proliferation of myeloid cells (maturing cells) which are mainly granulocytes, in blood and bone marrow.
- Occur mainly in adults
- Slow onset and long course

### **MPN** features


- Cytosis
- Organomegaly (mainly splenomgaly)
- High uric acid
- Hypercellular bone marrow
- Progression to acute leukaemia (mainly AML)

### **Chronic Myeloid Leukemia (CML)**

- •Stem cell MPN.
- Predominant proliferation of granulocytic cells.
- Consistently associated with the *BCR-ABL1* fusion gene located in the Philadelphia (Ph) chromosome which results from t(9;22).





### **Pathogenesis of CML**



Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

### **Pathogenesis of CML**





### **Clinical Presentation**

- ➤ Asymptomatic presentation(20-40%):
- > Routine CBC : marked leukocytosis
- > Common symptoms : Fatigue ,weight loss or night sweating
- > Abdominal discomfort due to splenomegaly
- Splenomegaly (Massive )




# **Main Differential Diagnosis**


- 1- Chronic myelomonocytic leukemia (monocytosis ,BCR-ABL –ve).
- 2-Leukemoid reaction: Leukocytosis due to physiological response to stress or infection


	CML	Leukaemoid
Age	Adult	Any age
WBC count	High	High but <100,000
Differential	Mainly myelocytes and segmented	Mainly Bands
Morphology	Hypogranular	Toxic
Splenomegaly	+	-/+
NAP score	Low	High
BCR/ABL	+ve	-ve
Onset	Chronic	Acute

# Neutrophil Alkaline Phosphatase (NAP)score:

•Cytochemical stain that estimate the amount of alkaline phosphatase enzyme in neutrophilis .







### **CML Phases**

### Chronic phase


- Leukocytosis (12-1000×10<sup>9</sup>/L)
- Mainly neutrophils & myelocytes
- Blasts ≤10% ,Basophils≤ 20%
- Stable course (years)


### Accelerated phase

- Increasing counts
- 10-19% blasts (basophils ≥20%)
- Unstable course (months)


### Blastic phase

- ≥20% blasts = Acute Leukemia
- 80% AML & 20% ALL
- (coarse: Weeks)





### **CML Treatment**





- •Targeted therapy (tyrosine kinase inhibitors like Imatinib)
- •Excellent response (5y overall survival≥ 90%)
- •If no response; stem cell transplantation


### **Myelodysplastic Syndromes MDS**

- Group of myeloid neoplasms characterized by:
  - 1-Peripheral cytopenia (Low HB ± Low WBC & Low PLT)
  - 2- Dysplasia (abnormal morphology)
  - 3- Ineffective hematopoiesis (hypercellular marrow)
  - 4-Progression to AML (preleukaemic disease)
  - **5-Enhanced apoptosis**

## **Myelodysplastic Syndromes MDS**








### **Myelodysplastic Syndromes MDS**

- Many subtypes according to:
  - 1-Blast count
  - 2-Degree of dysplasia
  - **3-Genetics**
- Variable genetic abnormalities mainly -5, -7
- Treatment : supportive +/- chemotherapy

### **Chronic Myelomonocytic Leukemia (CMML)**

- Clonal Hematopoietic malignancy characterized by proliferation of both monocytes and neutrophils.
- MDS/MPN disease:
  - \* Features of MDS (dysplasia& enhanced apoptosis)
  - \*Features of MPN (marked proliferation)
- Philadelphia chromosome must be negative
- Blast must be less than 20%.

### **CMML**



- Aggressive course (survival rate around 2.5 y)
- Treatment : Chemotherapy ±SCT

# MPN vs. MDS vs. MPN/MDS

